|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- March 6, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said new data has been published in the journal Molecular Therapy describing the development of lipidoid formulations for the systemic delivery of small interfering RNAs (siRNAs), the molecules that mediate RNAi. Lipidoids are a new class of lipid-based molecules which are used to form novel nanoparticle formulations for systemic delivery of RNAi therapeutics. The research was conducted by Alnylam scientists and collaborators from the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
Bradmer Pharmaceuticals Inc., of Toronto, implemented a restructuring plan ...